by TractManager | Apr 27, 2020 | Clinical Utility Evaluation
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use...
by TractManager | Apr 23, 2020 | Emerging Technology Report
Trodelvy (sacituzumab govitecan-hziy) is an intravenously administered antibody-drug conjugate (ADC) indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic...
by TractManager | Apr 23, 2020 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score testfor patients diagnosed with estrogen receptor–positive, human epidermal growth factor 2–negative, and node-negative invasive breast...
by TractManager | Apr 23, 2020 | Emerging Technology Report
Trodelvy (sacituzumab govitecan-hziy) is an intravenously administered antibody-drug conjugate (ADC) indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic...
by TractManager | Apr 17, 2020 | Health Technology Assessment
Focus of the Report: Implantation of the ProACT device for the treatment of adult men with post-prostate surgery urinary incontinence (UI).Technology Description: The ProACT system is a medical implantable device that consists of 2 sets of urethral balloons connected...
Recent Comments